The city of Memphis, Tennessee, currently has 7 active clinical trials seeking participants for Parkinson's Disease research studies.
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
NCT05642442
Recruiting
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tas... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
04/29/2024
Locations: Veracity Neuroscience LLC, Memphis, Tennessee
Conditions: Parkinson Disease, Tremor
Register for Updates
AMX0035 and Progressive Supranuclear Palsy
NCT06122662
Recruiting
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
04/25/2024
Locations: Veracity Neuroscience, LLC, Memphis, Tennessee
Conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Register for Updates
Early Parkinson's Disease Monotherapy With CVN424
NCT06006247
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
04/24/2024
Locations: Veracity Neuroscience, Memphis, Tennessee
Conditions: Parkinson's Disease
Register for Updates
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
NCT05424276
Recruiting
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. F... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
03/11/2024
Locations: Neurology, Memphis, Tennessee
Conditions: Parkinson Disease
Register for Updates
STEM-Parkinson's Disease
NCT04797611
Recruiting
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/02/2024
Locations: Veracity Neuroscience, Memphis, Tennessee
Conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism
Register for Updates
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Memphis, Tennessee
Conditions: Parkinson Disease
Register for Updates
Trial of Parkinson's And Zoledronic Acid
NCT03924414
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: Veracity Neuroscience LLC, Memphis, Tennessee
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Register for Updates